12:01 PM
Feb 05, 2019
 |  BC Extra  |  Politics & Policy

Senators push pharma CEOs on drug prices

Editor's Note: This article was updated on Feb 05, 2019 at 3:30 PM PST

Inquiries from Congress continue to pile up with a growing focus on rising costs of insulin, as senators press pharmaceutical companies yet again to disclose drug pricing information.

Senate Health, Education, Labor and Pensions (HELP) Committee Ranking Member Sen. Patty Murray (D-Wash.) sent letters Tuesday to insulin manufacturers Sanofi (Euronext:SAN; NASDAQ:SNY), Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) requesting details about the rising cost of insulin over time and recent decisions to raise prices further. The Senate...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >